- Main
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
- Rugo, Hope S;
- Campbell, Mike;
- Yau, Christina;
- Jo Chien, A;
- Wallace, Anne M;
- Isaacs, Claudine;
- Boughey, Judy C;
- Han, Hyo S;
- Buxton, Meredith;
- Clennell, Julia L;
- Asare, Smita M;
- Steeg, Katherine;
- Wilson, Amy;
- Singhrao, Ruby;
- Matthews, Jeffrey B;
- Perlmutter, Jane;
- Fraser Symmans, W;
- Hylton, Nola M;
- DeMichele, Angela M;
- Yee, Douglas;
- Van’t Veer, Laura J;
- Berry, Donald A;
- Esserman, Laura J
Published Web Location
https://doi.org/10.1007/s10549-024-07555-9Abstract
PurposeWe investigated the small-molecule receptor tyrosine kinase-inhibitor of colony-stimulating factor-1 receptor pexidartinib in the stage II/III breast cancer in the I-SPY2 platform trial.MethodsI-SPY2 is an adaptive platform trial that features multiple arms of experimental agents administered on a background of standard neoadjuvant therapy with paclitaxel and adriamycin/cyclophosphamide, followed by definitive surgery. The adaptive randomization engine preferentially assigns patients based upon cumulative performance of each agent in a given breast cancer subtype based on hormone receptor and HER2 receptor status. The study endpoint is pathologic complete response.ResultsA total of 9 participants were randomized to receive pexidartinib with neoadjuvant paclitaxel before enrollment was halted due to a serious adverse event of vanishing bile duct syndrome. No participants received a full course of the study drug.ConclusionAlthough there remains interest in agents targeting CSF-1, hepatic toxicity appears to be a limiting factor for their use in early breast cancer.Trial registrationNCT01042379 (www.clinicaltrials.gov/ct2/show/NCT01042379).
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.